High Note Wealth LLC Sells 69 Shares of Johnson & Johnson (NYSE:JNJ)

High Note Wealth LLC lowered its stake in shares of Johnson & Johnson (NYSE:JNJ) by 1.4% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 4,812 shares of the company’s stock after selling 69 shares during the period. High Note Wealth LLC’s holdings in Johnson & Johnson were worth $780,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in JNJ. Putnam Investments LLC increased its position in Johnson & Johnson by 0.3% during the fourth quarter. Putnam Investments LLC now owns 624,978 shares of the company’s stock worth $97,959,000 after buying an additional 2,128 shares during the last quarter. Kestra Advisory Services LLC raised its stake in Johnson & Johnson by 3.9% in the 4th quarter. Kestra Advisory Services LLC now owns 328,605 shares of the company’s stock valued at $51,505,000 after acquiring an additional 12,265 shares during the period. Waverly Advisors LLC lifted its holdings in Johnson & Johnson by 45.9% during the 4th quarter. Waverly Advisors LLC now owns 77,334 shares of the company’s stock valued at $12,121,000 after purchasing an additional 24,318 shares during the last quarter. Pinnacle Holdings LLC boosted its holdings in shares of Johnson & Johnson by 5.4% during the 4th quarter. Pinnacle Holdings LLC now owns 13,265 shares of the company’s stock worth $2,079,000 after buying an additional 685 shares during the period. Finally, Pathstone Holdings LLC acquired a new position in Johnson & Johnson in the 4th quarter valued at about $55,434,000. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Trading Up 0.6 %

NYSE:JNJ opened at $160.68 on Thursday. The firm’s fifty day moving average is $162.59 and its 200-day moving average is $154.36. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.85 and a current ratio of 1.07. Johnson & Johnson has a 52 week low of $143.13 and a 52 week high of $168.85. The firm has a market cap of $386.71 billion, a P/E ratio of 10.02, a P/E/G ratio of 2.69 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, July 17th. The company reported $2.82 EPS for the quarter, beating analysts’ consensus estimates of $2.71 by $0.11. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The company had revenue of $22.45 billion for the quarter, compared to analyst estimates of $22.33 billion. During the same period in the prior year, the firm posted $2.80 EPS. The company’s quarterly revenue was up 4.3% on a year-over-year basis. Equities analysts expect that Johnson & Johnson will post 10.02 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th were paid a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.09%. The ex-dividend date was Tuesday, August 27th. Johnson & Johnson’s dividend payout ratio is currently 30.92%.

Insider Activity

In other news, VP Robert J. Decker sold 5,635 shares of the company’s stock in a transaction on Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the sale, the vice president now directly owns 18,973 shares of the company’s stock, valued at approximately $3,131,683.38. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 0.16% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. Daiwa Capital Markets downgraded Johnson & Johnson from an “outperform” rating to a “neutral” rating and dropped their target price for the stock from $160.00 to $150.00 in a report on Tuesday, July 23rd. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a report on Monday, September 30th. The Goldman Sachs Group dropped their price target on Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating for the company in a research note on Friday, July 19th. Royal Bank of Canada increased their price objective on shares of Johnson & Johnson from $175.00 to $178.00 and gave the stock an “outperform” rating in a research note on Tuesday. Finally, StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, September 14th. Seven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $173.43.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.